Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The SUR1-TRPM4 channel complex is a heteromeric ion channel composed of the regulatory sulfonylurea receptor 1 (SUR1) and the pore-forming transient receptor potential melastatin 4 (TRPM4) subunit (Simard et al., 2007, Nature Medicine). Under physiological conditions, this complex is minimally expressed in the central nervous system; however, it is rapidly upregulated de novo in neurons, astrocytes, and capillary endothelium following acute injuries such as ischemic stroke, traumatic brain injury, and spinal cord injury (Simard et al., 2006, Journal of Neuroscience). Activation of the channel occurs in response to depleted intracellular ATP and elevated calcium levels, leading to a non-selective influx of monovalent cations that drives cytotoxic edema and oncotic cell death (Gerzanich et al., 2009, Journal of Cerebral Blood Flow & Metabolism). This process contributes significantly to blood-brain barrier breakdown and secondary brain swelling. Targeting the SUR1-TRPM4 complex with inhibitors like glibenclamide (BIIB093) aims to reduce edema and improve neurological recovery by blocking this pathological ion flux (Sheth et al., 2016, Lancet Neurology). This therapeutic approach is currently being evaluated in clinical trials for large hemispheric infarction and other forms of acute brain injury.
Inhibition of the SUR1-TRPM4 complex prevents the pathological influx of monovalent cations, thereby mitigating cytotoxic edema, oncotic cell death, and blood-brain barrier disruption in acute central nervous system injuries (Simard et al., 2012, Pharmaceuticals).
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sulfonylurea receptor 1-Transient receptor potential melastatin 4 channel complex (SUR1-TRPM4) (SUR1-TRPM4).